US · TCRX
TScan Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Waltham, MA 02451
- Website
- tscan.com
Price · as of 2024-12-31
$1.22
Market cap 60.15M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.14 | +2,288.52% |
| Intrinsic Value(DCF) | $1.25 | +2.46% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $85.05 | +6,871.31% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $4.00 | $242.56 | $42,163.97 | $0.00 | $0.00 |
| 2022 | $2.93 | $17.53 | $0.63 | $0.00 | $0.00 |
| 2023 | $6.55 | $29.64 | $1.45 | $0.00 | $0.00 |
| 2024 | $1.98 | $29.14 | $0.77 | $0.00 | $85.05 |
AI valuation
Our deep-learning model estimates TScan Therapeutics, Inc.'s (TCRX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.14
- Current price
- $1.22
- AI upside
- +2,288.52%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.25
+2.46% upside
Graham-Dodd
—
— upside
Graham Formula
$85.05
+6,871.31% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TCRX | TScan Therapeutics, Inc. | $1.22 | 60.15M | +2,289% | +2% | — | +6,871% | -1.74 | 0.92 | 78.74 | -0.24 | — | 0.92 | 100.00% | -4787.68% | -4527.66% | -65.08% | -271.01% | -39.64% | 0.40 | -36.91 | 8.14 | 8.07 | 0.68 | -1618.00% | -8662.00% | 7774.00% | -51.70% | -3.08 | -230.45% | 0.00% | 0.00% | 18.21% | -0.22 | -0.25 | 10.30 | -0.75 |
| ACET | Adicet Bio, Inc. | $7.25 | 69.44M | — | — | — | — | -0.60 | 0.37 | — | 0.81 | — | 0.37 | 0.00% | — | — | -65.65% | -433.12% | -54.79% | 0.09 | -31903.75 | 9.29 | 9.09 | 0.35 | -5982.00% | — | -477.00% | -133.68% | -4.76 | -317.32% | 0.00% | 0.00% | 0.00% | 0.70 | 0.95 | — | -2.95 |
| ACRV | Acrivon Therapeutics, Inc… | $1.51 | 47.65M | — | — | — | — | -2.63 | 1.20 | — | -0.46 | — | 1.20 | 0.00% | — | — | -54.07% | 26706.29% | -48.11% | 0.02 | — | 10.55 | 10.43 | 0.45 | -2336.00% | — | 5579.00% | -32.26% | -3.81 | 20490.12% | 0.00% | 0.00% | 2.26% | -0.41 | -0.53 | — | 4.53 |
| FBIO | Fortress Biotech, Inc. | $3.42 | 106.15M | +410% | -82% | — | +1,342% | -0.26 | 1.41 | 0.55 | -0.49 | — | -3.51 | 63.80% | -191.38% | -79.75% | -533.80% | -308.14% | -77.53% | 3.34 | -11.12 | 1.27 | 0.95 | -0.18 | -6824.00% | -3176.00% | -3017.00% | -297.40% | -1.12 | -265.74% | 14.72% | -3.90% | 14.72% | -0.46 | -0.53 | 0.88 | -9.03 |
| IMUX | Immunic, Inc. | $1.02 | 100.66M | — | — | — | — | -16.98 | -247.31 | — | -16.85 | — | -247.31 | 0.00% | — | — | -1653.15% | 539.27% | -299.36% | -0.02 | — | 0.75 | 0.64 | 0.16 | -3800.00% | — | 110.00% | -5.21% | -2.80 | 449.10% | 0.00% | 0.00% | 0.00% | -15.84 | -19.02 | — | -17.75 |
| LITS | Lite Strategy, Inc. | $1.13 | 41.55M | +12,712% | — | — | — | -1.77 | 1.66 | — | -0.60 | — | 1.66 | 0.00% | — | — | -63.84% | 545.04% | -53.45% | 0.00 | — | 13.50 | 13.30 | 1.05 | -18951.00% | -10000.00% | -5871.00% | -73.96% | -15.39 | 650.87% | 0.00% | 0.00% | 50.76% | -0.58 | -0.49 | — | -20.49 |
| NTRB | Nutriband Inc. | $4.44 | 54.06M | +340% | -57% | — | — | -4.78 | 7.79 | 23.39 | -4.51 | -10.98 | 11.26 | 32.68% | -312.62% | -489.86% | -162.94% | -157.60% | -139.89% | 0.03 | -312.51 | 4.88 | 4.46 | 0.41 | 4348.00% | 262.00% | 3184.00% | -9.43% | -4.71 | -111.17% | 0.00% | 0.00% | 8.03% | -6.87 | -9.73 | 21.47 | 19.59 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.70 | 90.46M | — | — | — | — | -1.08 | 0.36 | — | 1.42 | — | 0.36 | 0.00% | — | — | -29.23% | -306.66% | -26.48% | 0.01 | — | 12.22 | 11.79 | 0.54 | -2096.00% | — | -827.00% | -81.87% | -3.57 | -237.51% | 0.00% | 0.00% | 24.06% | 1.23 | 2.02 | — | -0.66 |
| RLMD | Relmada Therapeutics, Inc… | $4.56 | 334.4M | — | — | — | — | -0.11 | 0.24 | — | 0.43 | — | 0.24 | 0.00% | — | — | -132.33% | 824.32% | -111.57% | 0.00 | — | 4.45 | 4.36 | 0.05 | -1921.00% | — | 19.00% | -597.84% | -5.03 | 508.56% | 0.00% | 0.00% | 0.00% | 0.43 | 0.70 | — | -24.19 |
| XBIT | XBiotech Inc. | $2.26 | 68.9M | — | — | — | — | -2.57 | 0.54 | — | 1.76 | -4.62 | 0.54 | 0.00% | — | — | -19.21% | -219.51% | -18.10% | 0.06 | -52.63 | 11.56 | 11.49 | 4.51 | 5556.00% | — | 6905.00% | -32.59% | -2.05 | -166.91% | 0.00% | 0.00% | 0.00% | 1.49 | 1.97 | — | 3.15 |
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
- CEO
- Gavin MacBeath
- Employees
- 200
- Beta
- 1.04
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.25 ÷ $1.22) − 1 = +2.46% (DCF, example).